title: Novel immunological approaches for the treatment of Alzheimer's disease.
abstract: Alzheimer's disease (AD), the most prevalent form of dementia worldwide, can be deemed as the next global health epidemic. The biochemistry underlying deposition of amyloid beta (A β) and hyperphosphorylated tau aggregates in AD has been extensively studied. The oligomeric forms of A β that are derived from the normal soluble A β peptides are believed to be the most toxic. However, it is the fibrillar Aβ form that aggregates as amyloid plaques and cerebral amyloid angiopathy, which serve as pathological hallmarks of AD. Moreover, deposits of abnormally phosphorylated tau that form soluble toxic oligomers and then accumulate as neurofibrillary tangles are an essential part of AD pathology. Currently, many strategies are being tested that either inhibit, eradicate or prevent the development of plaques in AD. An exciting new approach on the horizon is the immunization approach. Dramatic results from AD animal models have shown promise for active and passive immune therapies targeting A β. However, there is very limited data in humans that suggests a clear benefit. Some hurdles faced with these studies arise from complications noted with therapy. Encephalitis has been reported in trials of active immunization and vasogenic edema or amyloid - related imaging abnormalities (ARIA) has been reported with passive immunization in a minority of patients. As yet, therapies targeting only tau are still limited to mouse models with few studies targeting both pathologies. As the majority of approaches tried so far are based on targeting a self - protein, though in an abnormal conformation, benefits of therapy need to be balanced against the possible risks of stimulating excessive toxic inflammation. For better efficacy, future strategies will need to focus on the toxic oligomers and targeting all aspects of AD pathology.
authors.affiliation: Department of Neurology, New York University School of Medicine, New York, USA.
authors.forename: Priyanka
authors.initials: P
authors.lastname: Sabharwal
authors.affiliation: Department of Neurology, New York University School of Medicine, New York, USA ; Department of Pathology, New York University School of Medicine, New York, USA ; Department of Psychiatry, New York University School of Medicine, New York, USA.
authors.forename: Thomas
authors.initials: T
authors.lastname: Wisniewski
keywords: Alzheimer disease; Amyloid beta - protein; Immunotherapy; Microtubule - associated proteins; Review